Fusions play a significant role in cancer biology, accounting for up to 17% of driver mutations in solid tumors and up to 40% in soft tissue sarcomas. Detecting these critical events is essential for advancing comprehensive genomic profiling (CGP) and biomarker discovery. However, challenges such as the diversity of fusion partners and the impact of formalin-fixed, paraffin-embedded (FFPE) sample degradation demand more sophisticated solutions.
Explore how optimized next-generation sequencing (NGS) assays can help overcome these barriers and drive more accurate, meaningful discoveries in cancer research.
This white paper highlights how Archer™ Anchored Multiplex PCR (AMP™) technology outperforms traditional opposing-primer methods like Thermo Fisher Scientific™ Oncomine™ Comprehensive Assay (OCA), delivering superior fusion detection even in challenging FFPE samples.
Expose critical gaps in traditional fusion detection: Learn about major risks in conventional opposing-primer approaches.
Unlock greater flexibility with sequencing platforms: Discover how Archer’s AMP-based solutions are broadly compatible with a range of sequencers, making it easier to integrate into existing research workflows.
Elevate your fusion detection performance: See how AMP technology overcomes the limitations of traditional assays by capturing more diverse and novel fusions—even in degraded FFPE samples.